Better Health for All
-30
NeoGenomics' core business is cancer diagnostics and drug development support, with 90% of its revenue from clinical cancer testing.
1
The company offers over 600 tests, served nearly 700,000 patients in 2024, and aims to serve 1 million patients annually by 2028, indicating a transformative health impact.
2
The company has no products with negative health impacts, as all offerings provide measurable health benefits, and has been providing testing for over 20 years.
3
The company's R&D expenses were $27.3 million in 2023, representing 4.1% of its $661 million revenue.
4
In terms of health externalities, the company reported 6,247.96 metric tons of CO2e in 2024 and a 27% recycling rate, with plans to be foam-free in kits by the end of 2025.
5
The company has a Diversity, Equity, Inclusion, and Belonging (DEIB) Council and a patient financial assistance program, but no specific funding or reach data is provided.
6
Voluntary employee turnover dropped to 10.2% in 2024, and women comprise 59.1% of the global workforce.
7
Preventative health measures are limited to flu vaccine clinics and a wellness program for employees.
8
The company adheres to HIPAA, GDPR, and CCPA, with annual training for relevant employees, and invests in leading technologies to secure data.
9
During Hurricane Ian, personnel were back in the Fort Myers lab within 48 hours.
10
Mental health support includes an Employee Assistance Program and a partnership with Project Helping.
11
For clinical trial ethics, the company supports pharmaceutical firms in drug development and clinical trials, implementing processes to ensure human subject rights are observed, but no specific data on ethical standards or diversity is provided.
12
Fair Money & Economic Opportunity
0
NeoGenomics, Inc. is a cancer diagnostics and pharma services company, not a financial institution offering lending or deposit services to consumers. Therefore, many KPIs related to financial products and services are not applicable. The company does not offer consumer credit products, nor does it generate revenue from high-cost financial products or penalty fees.
1
NeoGenomics provides patients with the right to access and obtain a copy of their Protected Health Information (PHI) and can request it be provided electronically and sent to another person electronically.
2
It also offers oncology data solutions involving the licensing of de-identified data to pharmaceutical and biotech clients.
3
Fair Pay & Worker Respect
30
For the 2024 fiscal year, NeoGenomics' CEO to median employee pay ratio was 117:1, with the CEO earning $11,338,487 and the median employee earning $97,169.
1
The company's Total Recordable Incident Rate (TRIR) for 2023 was 0.41, with 9 OSHA recordable injuries.
2
The median base pay ratio for female to male teammates was approximately 0.86:1, and for persons of color (POC) to non-POC teammates (US-based only) was approximately 0.79:1.
3
The voluntary employee turnover rate for 2023 was 13%.
4
All full-time employees are eligible for employer-funded health insurance coverage, including medical, dental, vision, and telehealth options, beginning the first of the month following their hire date.
5
Fair Trade & Ethical Sourcing
-50
NeoGenomics' Code of Business Conduct and Ethics applies to all company officers, directors, teammates, and vendors, requiring ethical conduct in dealings with suppliers and prohibiting unfair practices.
1
An Anti-Bribery and Corruption program is in place to screen international vendors.
2
However, the articles do not provide a specific percentage of supplier contracts that include enforceable ethical-sourcing clauses, nor do they detail the specific enforcement mechanisms or audit rights within these contracts. Without a quantitative percentage for contracts, the KPI cannot be scored positively. No evidence was found for fair trade certification share, audit frequency, forced or child labour incidents, traceability coverage, remediation speed, materials risk index, or supplier diversity spend.
3
Honest & Fair Business
20
NeoGenomics has a formal whistleblower policy with a hotline hosted by a third-party provider (EthicsPoint) for anonymous or confidential reporting.
1
The company prohibits retaliation, and all employees and managers receive annual training on hotline use and non-retaliation.
2
The board's composition shows 90% of directors are independent, and all four board committees are composed solely of independent directors.
3
The company maintains an Anti-Bribery and Corruption program, which includes screening and onboarding international vendors using the Diligent application, and actively screening vendors against media or sanction hits.
4
No corruption-related incidents were reported in 2023.
5
However, the extent of independent verification of ethical claims is limited to CAP and CLIA certifications for laboratories and the use of a third-party hotline provider, with no broader verification of ethical claims for approximately 50% of claims.
Kind to Animals
0
NeoGenomics, Inc. is listed as a company that uses animal testing.
1
The company is also on the Cruelty Free Investing list for exploiting animals due to its genetic and molecular testing services.
2
No War, No Weapons
-60
NeoGenomics, Inc. became a signatory to the United Nations Global Compact in 2020, which indicates support for UN Guiding Principles in principle, but implementation details are uneven.
1
The company initiated discussions on human rights, anti-bribery, anti-corruption, and conflict minerals as part of its quarterly business reviews with limited key suppliers in 2023, but no results of these reviews are published.
2
The company has initiated discussions on conflict minerals with limited key suppliers, but no specific percentage of the supply chain certified conflict-free is provided, and insufficient information from suppliers prevents determining the origin of conflict minerals.
3
Planet-Friendly Business
-50
NeoGenomics reported total Scope 1 and 2 GHG emissions of 4,717 metric tons CO2e for 2023, covering two sites representing approximately 70% of its testing volume.
1
The company does not provide Scope 3 emissions data for its main operations.
2
A subsidiary, Neology UK Ltd, reported 2023 emissions of 61.31 tCO2e (Scope 1, 2, and 3) and 2024 emissions of 140.23 tCO2e.
3
Neology UK Ltd has a net-zero target year of 2050.
4
NeoGenomics has several facilities with LEED certification, including its Fort Myers headquarters and properties in California, Arizona, Georgia, Suzhou (China), Rolle (Switzerland), and Singapore.
5
The company reported a waste recycling rate of 24.5% for 2023, with specific sites showing 21.1% and 36.0% for recycled waste.
6
Additionally, 99.4% of hazardous waste was recycled at its Aliso Viejo, CA site.
7
The company reported zero EPA reportable incidents in 2023.
8
A subsidiary, Neology UK Ltd, has a target to reduce packaging material by 15%.
9
Respect for Cultures & Communities
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities'. Information regarding formal partnerships with indigenous or local community groups
1
, revenue reinvested in local community development
2
, cultural appropriation incidents
3
, cultural impact assessment protocols
4
, local employment ratios
5
, grievance mechanisms for community concerns
6
, average complaint resolution time
7
, FPIC participation rates
8
, community governance inclusion
9
, cultural preservation investment
10
, local procurement share
11
, indigenous supplier count
12
, cultural site protection
13
, social license to operate
14
, charitable giving to cultural heritage organizations
15
, community fund allocation
16
, language inclusivity
17
, cultural incident response
18
, or cultural sensitivity training completion
19
is explicitly stated as absent or not provided across all articles.
Safe & Smart Tech
0
NeoGenomics experienced one minor data breach affecting 911 patients, involving the accidental disclosure of Protected Health Information (PHI) via an email attachment in January.
1
This incident, which included data from January 2018 to October 2019, led to additional HIPAA training for the employee and instructions for the workforce to verify document accuracy.
2
The company states it has invested in leading technologies to secure data and implements various security measures, including Secure Sockets Layer (SSL) technology for encryption during transmission.
3
NeoGenomics operates CAP-accredited and CLIA-certified laboratories in multiple locations.
4
The company adheres to various data protection laws, including HIPAA, GDPR, and CCPA, and provides transparency and choice to patients regarding data handling through its Notice of Privacy Practices.
5
It also attempts to collect the minimal amount of information necessary for services and payment.
6
Access to personal information is restricted to authorized personnel who need it to perform services.
7
Users can request removal of their personal information, revoke consent for sharing, and opt out of communications.
8
Personal information is protected by user-created passwords for online accounts.
9
The company's 2023 ESG report indicates that U.S. teammates undergo HIPAA training upon onboarding and annually, international teammates receive GDPR training, and all new hires receive CCPA training, with ad-hoc privacy trainings as needed.
10
In 2023, teammates completed over 260,000 courses, averaging nearly 125 courses per person, including required compliance and privacy courses.
11
The company is not aware of any cybersecurity threats that have materially affected its business strategy, results of operations, or financial condition, as stated in its February 2025 10-K filing.
12
Zero Waste & Sustainable Products
-40
In 2023, NeoGenomics recycled 21.1% of its total waste.
1
The company recycled 99.4% of its hazardous waste in 2023, and 20.3% of its non-hazardous waste.
2
NeoGenomics has implemented several waste reduction initiatives, including the NeoGreen program which recycled 310 tons of waste from two labs in 2023, and the elimination of foam inserts from test kits, replacing them with SBS 34pt. board inserts.
3
The company reported zero EPA reportable incidents in 2023.
4
NeoGenomics has set waste-related goals for 2024, which include conducting a site waste management assessment and implementing an educational campaign to encourage best waste management practices.
5
The company acknowledges a need to push suppliers for reusable or biodegradable options but does not detail specific requirements.
6